



GRANT CYCLE 6 (2021-2024)

The Global Fund to Fight AIDS, Tuberculosis, and Malaria operates on a structured grant cycle, typically lasting three years, though this duration can vary based on specific program needs and circumstances. World Vision has been implementing Global Fund grants since the organization's inception in 2002, spanning multiple grant cycles. This section of the report highlights World Vision's coverage and cumulative achievements during Grant Cycle 6, which spanned from January 2021 to December 2023. It must be noted that PNG received a costed extension for Grant Cycle 6 until December 2024, while Eswatini's grant runs until September 2024, and Angola and Malawi's grants continued until June 2024.


Highlights

In Grant Cycle 6, World Vision's total portfolio was valued at \$444,741,411, including \$65 million (15%) in C19 funding. This funding was distributed across eight Principal Recipient (PR) awards in seven countries and eleven Sub-Recipient/Sub-Sub-Recipient (SR/SSR) awards in eight countries, reaching over 88 million beneficiaries.

Coverage

	PR	SR	SSR
HIV		Kenya, Eswatini	
TB	Somalia	Kenya, India, Senegal, Myanmar	India
Malaria	Malawi, Mozambique, CAR	Angola, Zimbabwe	Thailand
HIV/TB	Nicaragua, Haiti, PNG, Malawi	Thailand	

Budget



Beneficiaries

Number of Beneficiaries - Malaria	84,705,372
Number of Beneficiaries - TB	726,742
Number of Beneficiaries - HIV/TB	2,636,888
Total number of Beneficiaries	88,069,002


4.1 MALARIA FACT SHEET

In this grant cycle, World Vision was a Principal Recipient of malaria grants in CAR, Mozambique, and Malawi, and a Sub-Recipient in Angola, Thailand, and Zimbabwe, with a combined budget of \$ 206.2 million, which includes \$37.3 million in C19 funding reaching over 84.7 million beneficiaries.

Coverage

	PR	SR	SSR
Malaria	Malawi, Mozambique, CAR	Angola, Zimbabwe	Thailand

Budget



Beneficiaries

Indicator	2021	2022	2023	Total
Case Management				
Testing	17,393,784	8,918,163	6,372,399	32,684,346
Treatment				
• Received first-line anti-malarial treatment	9,308,040	7,196,051	5,552,235	22,056,326
• Pregnant women who received 3 doses of IPTp	85,889	178,985	94,416	359,290
Vector Control				
LLIN distributed (Mass + Continuous)	258,22	6,366,177	19,394,606	26,019,004
Structures sprayed with IRS	1	546,833	391,643	1,330,119
Beneficiaries	391,64			
Population protected by LLIN	258,221	11,132,060	34,601,972	45,992,254
Population protected by IRS	1,908,452	1,821,930	1,939,100	5,669,482
Total Beneficiaries (Testing + Vector Control)	19,646,346	22,051,138	43,007,887	84,705,372

- Our vector control efforts reached 51.6 million beneficiaries through the distribution of 26 million LLINs and the spraying of IRS for 1.3 million structures/households.
- Our case management efforts ensured 32.2 million suspected malaria cases received a parasitological test; 88% of whom received it in public sector health facilities, 9% in the community and 3% in private sector facilities.
- Our efforts also reached 22.4 million beneficiaries with treatment services. This includes 22 million confirmed malaria cases receiving first-line anti-malarial treatment and 359,290 pregnant women with three doses of intermittent preventive treatment for malaria.


4.2 HIV FACT SHEET

In GC6 World Vision's HIV/AIDS efforts included integrated HIV/TB programs in Papua New Guinea, Nicaragua, Haiti, and Malawi, where we served as Principal Recipients, and in Kenya, Swaziland, and Thailand, where we served as Sub-Recipients, with a total value of \$163.4 million for the cycle, reaching 2.6 million beneficiaries.

Coverage

	PR	SR
HIV		Kenya, Eswatini
HIV/TB	Nicaragua, Haiti, PNG, Malawi	Thailand

Budget



Beneficiaries

Indicator	2021	2022	2023	Total
Prevention				
Key population reached with defined package of services	331,465	354,519	487,081	1,173,065
Testing				
Individuals supported with knowing their HIV status	137,391	79,464	139,642	356,497
Treatment				
PLHIV supported with ART	171,771	159,462	171,340	502,573
Education				
Adolescent Education	522,094	620,204	750,079	1,892,377
Beneficiaries				
Total Beneficiaries	695,782	881,299	1,059,807	2,636,888

HIV Prevention Program: A total of 1,173,065 individuals from key populations were reached with HIV prevention programs offering a defined package of services

- **Men Who Have Sex with Men (MSM)** accounted for 12.1% of the total key populations reached, with 141,398 individuals engaged.
- **Transgender** Individuals represented 0.9%, with 10,040 individuals reached.
- **Sex Workers** constituted 19.9%, with 233,529 individuals engaged.
- **Adolescent Girls and Young Women** made up 63.9% of the total key populations reached, with 749,802 individuals benefiting from the programs.

HIV Testing: A total of 356,497 individuals from key populations were tested for HIV and received their results in GC6:

- **Men Who Have Sex with Men (MSM)** accounted for 34.1% of the total key populations tested, with 121,644 individuals receiving their results.
- **Transgender Individuals** represented 3.8%, with 13,365 individuals tested and knowing their results.
- **Sex Workers** constituted 39.6%, with 141,029 individuals tested and receiving their results.
- **Adolescent Girls and Young Women (AGYW)** made up 21.0% of the total key populations tested, with 74,979 individuals benefiting from the testing programs.
- **General Population (Women and Men aged 15+)** represented 1.5% of the total key populations tested, with 5,480 individuals receiving their results.

HIV Treatment: A total of 502,573 individuals from key populations were supported with ART and other eligible treatment in GC6:

- **Newly Diagnosed Individuals Initiated on ART:** A total of 178,074 people newly diagnosed with HIV were initiated on ART.
- **ART during Pregnancy/Labour:** 3,797 HIV-positive women received ART during pregnancy and/or labour and delivery.
- **ART during TB Treatment:** 2,095 new and relapsed HIV-infected TB cases received ART during TB treatment.
- **PLHIV Initiated on TB Preventive Therapy:** 24,293 PLHIV on ART initiated TB preventive therapy.
- **Total on ART:** The combined total on ART includes 294,314 individuals, with adults (15 years and older) constituting 96.3% (283,486) and children (under 15 years) constituting 3.7% (10,828).


4.3 TB FACT SHEET

In GC6 World Vision's HIV/AIDS efforts included integrated HIV/TB programs in Papua New Guinea, Nicaragua, Haiti, and Malawi, where we served as Principal Recipients, and in Kenya, Swaziland, and Thailand, where we served as Sub-Recipients, with a total value of \$163.4 million for the cycle, reaching 2.6 million beneficiaries.

Coverage

Disease Focus	PR	SR	SSR
TB	Somalia	Kenya, India, Senegal, Myanmar	India
HIV/TB	Nicaragua, Haiti, PNG, Malawi	Thailand	

Budget



Beneficiaries

	2021	2022	2023	GC6
Indicator	Achieved	Achieved	Achieved	Achieved
TB & MDR TB Case Detection and Notification				
Number of notified cases of all forms of TB	43,047	30,67	70,387	144,104
Number of cases of RR and/or MDR-TB reported.	682	0	1333	46,267
Treatment Success Rate		44,25		
Treatment success rate - all forms	0	290%	77	82%
Treatment success rate - MDR TB	0	87%	%	89%
TB Preventive Therapy			91	
Contacts of people with bacteriologically confirmed TB evaluated for TB	1285	12,9185	1%,6432	30,6902
Number of people in contact with TB patients who began preventive therapy	3181	15 4 , 617	45, 424	203,222
TPT Treatment completion rate		85%	70%	78%
HIV/TB				
TB patients with documented HIV status	8238	10,274	23,244	41,75
PLHIV on ART who initiated TB preventive therapy	22992	329	2926	6
				26,24

Total Notified TB Cases: We successfully notified 144,104 cases of all forms of TB (bacteriologically confirmed and clinically diagnosed, including new and relapse cases) and 46,267 MDR-TB cases.

High-Risk Group Notifications: The proportion of TB cases notified among high-risk groups (prisoners and other key populations) is approximately 1.7% (2,447 out of 144,104).

Non-NTP Contributions: Non-national TB program providers (private/non-governmental facilities and community referrals) contributed 7.8% of the total notified TB cases (11,143 out of 144,104).

Contact Investigation and TPT: A total of 306,902 contacts of individuals with bacteriologically confirmed TB were evaluated for TB. Approximately 66% of contacts evaluated (203,222 out of 306,902) started TB preventive therapy (TPT).

Treatment Success Rates: The treatment success rate for all forms of TB, MDR TB is 82% and 89% respectively and the treatment completion rate for TPT is 78%.